Prakash

Author's details

Name: Prakash Nallathamby
Date registered: July 27, 2017

Latest posts

Military Health Sciences Research Symposium 2024. (Aug 26-29, 2024, Kissimmee FL) — August 30, 2024
Sustained and Controlled Antibiotics Release for Prolonged Antibacterial Action Against MRSA, and Pseudomonas aeruginosa — August 21, 2024
Precision Health and Diagnostics Session Chair at Techconnect World Innovation Conference (2024) — June 19, 2024
MTEC Annual meeting in Baltimore MD (May 24, 2024) — May 24, 2024
Nallathamby Lab’s Kevin Armknecht is Invited to Present at the Midwest Microscopy and Microanalysis Workshop 2024 — May 7, 2024

Author's posts listings

Jan 29

Phage-Mimicking Antibacterial Nanoparticles Tackle Group A Streptococcal Infections In Vivo

Categories:

American Cancer Society, Berthiaume Institute for Precision Health, Hybrid nanoparticles, Indiana Clinical Translational Sciences Institute (I-CTSI), multidrug resistance

by Prakash

We are excited to publish on our Phage-mimicking nanoparticles efficiently tackling Group A Streptococcus infections in mouse wound infection models in RSC Nanoscale Advances (https://pubs.rsc.org/en/content/articlepdf/2024/NA/D3NA00620D). Thank you to Prof. Frank Castellino, Prof. Victoria Ploplis, and Deborah Donahue of the W.M. Keck Transgene Center for the in vivo studies. Thanks to Prof. Shaun Lee’s lab (Biology) …

This post has no tag

Oct 30

2nd Annual Berthiaume Institute for Precision Health’s Advisory Board Meeting

Categories:

antibiotics, Antimicrobial, Berthiaume Institute for Precision Health, Biomedical Imaging, Combination chemotherapy, Label-free, magnetoelectrics, multidrug resistance

by Prakash

Great job by the Nallathamby lab (PDNANO) members Conor, Kevin and Carlie at presenting our work on antibacterials, and cancer therapeutics to the @ND_IPH advisory board! Great input from the advisory board members on possible collaborations and translational paths forward. #GoIrish#NDResearch#MDR#curecancer All three presenters have publications with us which formed the basis for these poster …

This post has no tag

Aug 14

1st Place Poster at the Military Health Sciences Research Symposium 2023 (Aug 14-17, Kissimmee, FL)

Categories:

antibiotics, Antimicrobial, Berthiaume Institute for Precision Health, Conference abstracts

by Prakash

The Nallathamby group won 1st place at the DoD’s largest health conference (MHSRS’23) for our disruptive work tackling the biggest public health problem of Multidrug-resistant (MDR) bacterial infections. I am proud to represent ND among other distinguished participants! #GoIrish #NDresearch #mdr #MHSRS2023. Our work was titled, “Wound Healing Promoted by Broad-Spectrum, Phage Structure Mimicking, Synthetic …

This post has no tag

Jul 07

Congratulations to Ms. Johanna Olesk on Defending her MS (Bioengineering) ’23 Thesis

Categories:

antibiotics, Antimicrobial, Berthiaume Institute for Precision Health, Graduate Student, multidrug resistance, Thesis defense, Uncategorized

by Prakash

Congratulations to Nallathamby lab’s @JohannaOlesk on successfully defending her Masters thesis for Bioengineering in Summer 2023. Her thesis was titled ” Phage-Mimicking Nanoparticles Conjugated with Antimicrobial Peptides and Polymers as an Alternative to Antibiotic Treatment.” She passed with unanimous consent. We wish her all the best in her future undertakings. #WomenInSTEM#notredame#GoIrish Special mention to all …

This post has no tag

Jun 17

Translational Science to Impact Public Health was our Goal at Techconnect 2023

Categories:

antibiotics, Antimicrobial, Berthiaume Institute for Precision Health, multidrug resistance, Techconnect, Uncategorized

by Prakash

We were excited to present our work titled, “Biomimetic, Antibiotic Free, Nanoparticles for Agent Agnostic Broad Spectrum Antimicrobial Action including ESKAPE Pathogens” [Abstract 557] at the 2023 TechConnect World Innovation Conference in National Harbor, MD (June 19-21, 2023), as part of the Precision Health and Diagnostics symposium. Our talk was well received. We got lots of useful …

This post has no tag

May 23

Medical Technology Enterprise Consortium’s (MTEC) 8th Annual Meeting- Richmond, VA (May 23-24, 2023)

Categories:

antibiotics, Antimicrobial, Berthiaume Institute for Precision Health, Conference abstracts, multidrug resistance, Uncategorized

by Prakash

Nallathamby group’s work on “Phage-mimicking, Broad-spectrum, antibacterial nanoparticles” was showcased at MTEC’s annual meeting in Richmond, Virginia. I am proud to represent Notre Dame and the Berthiaume Institute for Precision Health at the 8th annual meeting of MTEC to learn firsthand the medical needs of the DoD. Our focus on combating antimicrobial resistance using phage …

This post has no tag

May 01

Argerie Guevara (CBE’23) Successfully Defends her Undergraduate Thesis

Categories:

antibiotics, Antimicrobial, Berthiaume Institute for Precision Health, multidrug resistance, Uncategorized

by Prakash

Congratulations to @Argerie Guevara (CBE’23) for taking the thesis option in her undergraduate research and passing it with unanimous consensus today. Her thesis was titled, “PLGA nanoparticles formulations loaded with antibiotics induce sustained and controlled antibiotics release for prolonged antibacterial action against MRSA, and Pseudomonas aeruginosa FRD1,” and is currently being peer-reviewed for publication. Argerie is currently …

This post has no tag

Nov 16

Nallathamby Lab is one of 20 Participants Invited to Present Phage-Mimicking Antibacterial Nanoparticle Prototype at the Inaugural Joint Innovation Medical Symposium (JIMS) at Pope Army Airfield/Fort Bragg (Nov 16-17, 2022)

Categories:

AD&T Notre Dame, antibiotics, Antimicrobial, Berthiaume Institute for Precision Health, Conference abstracts

by Prakash

In recent combat theaters, despite advances in treating critical injuries leading to higher survival rates, there has been an increase in the number of infections linked to trauma, particularly those caused by bacteria resistant to multiple drugs 1,2. Research from the Trauma Infectious Disease Outcomes Study indicates that 27% of those evacuated with injuries develop …

Tags: antibacterial, biomimetic, multidrug resistance

Sep 16

Nallathamby Lab Presents Phage-Mimicking Antibacterial Nanoparticle Results at Military Health Sciences Research Symposium 2022 in Orlando, Florida (Sept 12-15, 2022)

Categories:

antibiotics, Antimicrobial, Berthiaume Institute for Precision Health

by Prakash

We are losing in an antibiotic arms race with bacteria due to the emergence and global spread of new antibiotic resistance mechanisms.1,2 At current rates of antibiotics discovery and development we will eventually lose to antibiotic-resistant strains, and by 2050, antibiotics resistant strains of bacteria will kill more patients per year than all cancers combined. …

This post has no tag

Jul 07

CTSI-Think Tank Seed Funds our Efforts to facilitate CAR-T Therapy to Treat Solid Tumors.

Categories:

American Cancer Society, Berthiaume Institute for Precision Health, CAR-T, Grants funding

by Prakash

Breast Cancer is the most widespread cancer and the second leading cause of cancer-related deaths among women in the U.S.A. As a treatment option, gene-modified T cells are under active therapeutic consideration for both hematological and solid malignancies. As of 2016, there are 17 active TCR and 103 ongoing CAR-modified T cell studies registered through …

This post has no tag

NIH Funding Opportunities

NINR Resources and Related Research Projects in Firearm Injury Prevention (R24 Clinical Trial Not Allowed) November 21, 2024
Funding Opportunity RFA-NR-25-002 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications from multidisciplinary teams of experts in firearm injury prevention research across departments and institutions to develop and provide research resources and support to build capacity among United States (U.S.) nurse researchers for rigorous, high-impact research in […]
Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R41 - Clinical Trials Optional) November 21, 2024
Funding Opportunity RFA-DA-26-017 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research and development of medical devices specifically indicated for pediatric population (i.e., 0-21 years old, as defined by the FDA Center for Devices and […]
Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R43 - Clinical Trials Optional) November 21, 2024
Funding Opportunity RFA-DA-26-016 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research and development of medical devices specifically indicated for pediatric population (i.e., 0-21 years old, as defined by the FDA Center for Devices and […]
NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional) November 21, 2024
Funding Opportunity PAR-25-261 from the NIH Guide for Grants and Contracts. The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. […]
Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R21 Clinical Trial Not Allowed) November 21, 2024
Funding Opportunity RFA-MH-26-111 from the NIH Guide for Grants and Contracts. Eradicating latent reservoirs of HIV-1 within the body and achieving a sterilizing or functional cure have become priority areas in the AIDS field and NIH AIDS programs across many Institutes and Centers, including NIMH. In addition understanding the mechanisms of HIV- associated co-morbidities in […]
Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed) November 21, 2024
Funding Opportunity RFA-MH-26-110 from the NIH Guide for Grants and Contracts. Eradicating latent reservoirs of HIV-1 within the body and achieving a sterilizing or functional cure have become priority areas in the AIDS field and NIH AIDS programs across many Institutes and Centers, including NIMH. In addition understanding the mechanisms of HIV- associated co-morbidities in […]
Notice of Early Expiration of PAR-22-138, "Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)" November 21, 2024
Notice NOT-MH-25-076 from the NIH Guide for Grants and Contracts
Notice of Early Expiration of PAR-22-137, Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed) November 21, 2024
Notice NOT-MH-25-075 from the NIH Guide for Grants and Contracts
Notice of Early Expiration of "Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Universal Influenza Vaccine", NOT-AI-22-013 November 21, 2024
Notice NOT-AI-24-084 from the NIH Guide for Grants and Contracts
Webinar for Notice of Special Interest (NOSI): Training Modules for Enhancing Biomedical Research Workforce Training November 21, 2024
Notice NOT-GM-25-009 from the NIH Guide for Grants and Contracts

Nallathamby Laboratory

Modular and scalable nanotechnology for imaging, sensing and therapeutics

Prakash

Author's details

Latest posts

Author's posts listings

Phage-Mimicking Antibacterial Nanoparticles Tackle Group A Streptococcal Infections In Vivo

2nd Annual Berthiaume Institute for Precision Health’s Advisory Board Meeting

1st Place Poster at the Military Health Sciences Research Symposium 2023 (Aug 14-17, Kissimmee, FL)

Congratulations to Ms. Johanna Olesk on Defending her MS (Bioengineering) ’23 Thesis

Translational Science to Impact Public Health was our Goal at Techconnect 2023

Medical Technology Enterprise Consortium’s (MTEC) 8th Annual Meeting- Richmond, VA (May 23-24, 2023)

Argerie Guevara (CBE’23) Successfully Defends her Undergraduate Thesis

Nallathamby Lab is one of 20 Participants Invited to Present Phage-Mimicking Antibacterial Nanoparticle Prototype at the Inaugural Joint Innovation Medical Symposium (JIMS) at Pope Army Airfield/Fort Bragg (Nov 16-17, 2022)

Nallathamby Lab Presents Phage-Mimicking Antibacterial Nanoparticle Results at Military Health Sciences Research Symposium 2022 in Orlando, Florida (Sept 12-15, 2022)

CTSI-Think Tank Seed Funds our Efforts to facilitate CAR-T Therapy to Treat Solid Tumors.

Recent Posts

Recent Comments

Archives

Categories

Meta

NIH Funding Opportunities

Copyright